Atai Life Sciences N.V.

XTRA:9VC Stock Report

Market Cap: €191.4m

Atai Life Sciences Past Earnings Performance

Past criteria checks 0/6

Atai Life Sciences has been growing earnings at an average annual rate of 12.3%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been declining at an average rate of 58.3% per year.

Key information

12.3%

Earnings growth rate

33.4%

EPS growth rate

Pharmaceuticals Industry Growth7.3%
Revenue growth rate-58.3%
Return on equity-89.0%
Net Margin-38,852.9%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Atai Life Sciences makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

XTRA:9VC Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 240-1295450
30 Jun 240-585649
31 Mar 240-346154
31 Dec 230-406260
30 Sep 230-675869
30 Jun 230-1456676
31 Mar 230-1496576
31 Dec 220-1527074
30 Sep 220-1968165
30 Jun 221-1948160
31 Mar 220-20510158
31 Dec 2120-1689348
30 Sep 2120-16613938
30 Jun 2120-21812333
31 Mar 2120-1858815
31 Dec 200-1708111

Quality Earnings: 9VC is currently unprofitable.

Growing Profit Margin: 9VC is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 9VC is unprofitable, but has reduced losses over the past 5 years at a rate of 12.3% per year.

Accelerating Growth: Unable to compare 9VC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 9VC is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (25.4%).


Return on Equity

High ROE: 9VC has a negative Return on Equity (-88.99%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 04:18
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Atai Life Sciences N.V. is covered by 14 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Leonildo DelgadoBaader Helvea Equity Research
Sumant Satchidanand KulkarniCanaccord Genuity
Charles DuncanCantor Fitzgerald & Co.